Last reviewed · How we verify
PL 1
PL 1 is a medication used to treat atrial fibrillation.
PL 1 is a medication used to treat atrial fibrillation. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | PL 1 |
|---|---|
| Also known as | Placebo |
| Sponsor | Technical University of Munich |
| Drug class | Antiarrhythmic |
| Target | Potassium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
PL 1 works by blocking certain electrical signals in the heart, helping to restore a normal heart rhythm. It is often used in patients with atrial fibrillation who are at high risk of stroke or other complications.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Palpitations
- Dizziness
- Nausea
Key clinical trials
- Platelet Lysate vs Saline for Lumbosacral Radiculopathy (NA)
- Factors in Learning And Plasticity: Healthy Vision (NA)
- Factors in Learning And Plasticity: Macular Degeneration (NA)
- Transforaminal Lumbar Interbody Fusion (TLIF) (NA)
- Breathlessness Patterns in Patients With Cancer, COPD and Heart Failure: an fMRI Feasibility Study
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nuclear Extract (NA)
- Influence of Proprioceptive Reweighting Ability on Lower-limb Biomechanics During Functional Tasks (NA)
- Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PL 1 CI brief — competitive landscape report
- PL 1 updates RSS · CI watch RSS
- Technical University of Munich portfolio CI